Traynor Capital Management, Inc. Exelixis, Inc. Transaction History

Traynor Capital Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 24, 2019	SELL	$13.65 - $21.8 $286,076 - $456,884	-20,958 Closed	0 $0
Q3 2018 Oct 24, 2018	SELL	$15.87 - $22.4 $405,795 - $572,768	-25,570 Reduced 54.96%	20,958 $371,000
Q2 2018 Aug 03, 2018	BUY	$18.56 - $22.45 $496,350 - $600,380	26,743 Added 135.17%	46,528 $1.01 Million
Q1 2018 May 01, 2018	BUY	$22.15 - $31.89 $204,555 - $294,504	9,235 Added 87.54%	19,785 $438,000
Q4 2017 Feb 01, 2018	BUY	$24.23 - $30.93 $19,384 - $24,744	800 Added 8.21%	10,550 $320,000
Q3 2017 Oct 27, 2017	BUY	$23.35 - $29.24 $227,662 - $285,090	9,750	9,750 $236,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Traynor Capital Management, Inc. with notifications on news.